Darmstadt, Germany, April 27, 2018 — Merck, a leading science and technology company, today launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.
“Researchers increasingly require more power and agility in their labs and research capabilities,” said Jean-Charles Wirth, head of the Applied Solutions business unit, Life Science, at Merck. “Merck’s new CellStream™ flow cytometry system expands the limits of sensitivity, allowing scientists to tailor their instrument to their needs in immunology, cancer research and many other areas.”
The CellStream™ system’s Amnis® time-delay integration and camera technology rapidly captures low-resolution cell images and converts them to high-throughput intensity data with enhanced fluorescence sensitivity. The new system can be used in a wide variety of research areas, including exosome research, where it can identify small populations unable to be seen on other cytometers.Merck developed this new technology with the same patent-protected optics system as its Amnis® flow cytometers, which are used in academic, biotech and pharmaceutical cell analysis and research applications.
The CellStream™ flow cytometry system offers multiple innovative features, including:
The new CellStream™ system expands Merck’s portfolio of innovative flow cytometry platforms.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.